- Home
- STEC vs BIVI Comparison
STEC vs BIVI Comparison
Compare STEC & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- BIVI
- Stock Information
- Founded
- STEC 2006
- BIVI 2013
- Country
- STEC China
- BIVI United States
- Employees
- STEC N/A
- BIVI N/A
- Industry
- STEC
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- BIVI Health Care
- Exchange
- STEC NYSE
- BIVI Nasdaq
- Market Cap
- STEC 19.0M
- BIVI 18.8M
- IPO Year
- STEC 2021
- BIVI N/A
- Fundamental
- Price
- STEC $1.32
- BIVI $0.95
- Analyst Decision
- STEC
- BIVI Strong Buy
- Analyst Count
- STEC 0
- BIVI 1
- Target Price
- STEC N/A
- BIVI $30.00
- AVG Volume (30 Days)
- STEC 42.5K
- BIVI 230.4K
- Earning Date
- STEC 04-08-2025
- BIVI 05-13-2025
- Dividend Yield
- STEC N/A
- BIVI N/A
- EPS Growth
- STEC N/A
- BIVI N/A
- EPS
- STEC N/A
- BIVI N/A
- Revenue
- STEC $260,474,693.00
- BIVI N/A
- Revenue This Year
- STEC $9.76
- BIVI N/A
- Revenue Next Year
- STEC $15.85
- BIVI N/A
- P/E Ratio
- STEC N/A
- BIVI N/A
- Revenue Growth
- STEC N/A
- BIVI N/A
- 52 Week Low
- STEC $0.20
- BIVI $0.80
- 52 Week High
- STEC $3.25
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- STEC 49.39
- BIVI 37.09
- Support Level
- STEC $1.21
- BIVI $0.99
- Resistance Level
- STEC $1.54
- BIVI $1.10
- Average True Range (ATR)
- STEC 0.13
- BIVI 0.10
- MACD
- STEC -0.04
- BIVI 0.01
- Stochastic Oscillator
- STEC 30.90
- BIVI 34.07
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.